Discover groundbreaking updates in lymphoma and CLL treatments, including innovative therapies and promising trial results ...

In this installment of The OncoloGIST, Hans Lee, MD, director of Myeloma Research at Sarah Cannon Research Institute, ...

Liquid biopsy using circulating tumor DNA (ctDNA) is emerging as a valuable tool in early-stage NSCLC, with the potential to ...

The FDA approved T-DXd plus pertuzumab for HER2-positive metastatic breast cancer, based on DESTINY-Breast09 trial results. The combination therapy reduced disease progression or death risk by 44% ...

New research shows that patients receiving mismatched unrelated donor stem cell transplants achieve similar survival rates, regardless of HLA matching levels.

The TBCRC-056 trial showed a 50% pCR rate in TNBC patients with BRCA or PALB2 mutations treated with niraparib and dostarlimab. sTILs increased significantly in both treatment arms, with higher ...

RAD51-based assessment effectively identifies HER2-negative metastatic breast cancer patients likely to respond to olaparib, especially with BRCA1/2 or PALB2 variants. RAD51-low tumors showed a higher ...

Real acupuncture significantly improves objective cognitive health in breast cancer survivors compared to sham acupuncture and usual care. Both real and sham acupuncture exceed the minimum clinically ...

Nadunolimab combined with chemotherapy showed no significant efficacy improvement in metastatic TNBC, despite surpassing ...

The phase 3 MajesTEC-3 trial demonstrated that the combination of the bispecific BCMA-directed T-cell engager teclistamab and ...

Patients receiving Pola-R-CHP were found to be more likely to be male (58% vs 54%), younger (mean age, 75.0 vs 77.5 years), ...

A recently cleared phase 3 study (NCT06051409) will evaluate olverembatinib combined with chemotherapy as a first-line ...